Key result
SIRT1 activation attenuates Ang II-induced hypertensive cardiac remodeling and dysfunction by suppressing ferroptosis.
Why the study?
Whether SIRT1 alleviates hypertensive cardiac remodeling by regulating the FSP1-CoQ10 axis to inhibit ferroptosis and mitochondrial dysfunction was unknown.
Does SIRT1 activation alleviate hypertensive cardiac remodeling by regulating the FSP1-CoQ10 axis to inhibit ferroptosis and mitochondrial dysfunction in Angiotensin II-induced hypertensive mice and cardiomyocytes?
Does SIRT1 activation alleviate hypertensive cardiac remodeling by regulating the FSP1-CoQ10 axis to inhibit ferroptosis and mitochondrial dysfunction in Angiotensin II-induced hypertensive mice and cardiomyocytes?
Identifies the SIRT1-FSP1-CoQ10 axis as a protective mechanism against ferroptosis and mitochondrial dysfunction and a potential therapeutic target in hypertensive cardiac remodeling.
Answers are grounded in this paper and cite their sources.
Should not yet change hypertensive heart disease management; leaves open SIRT1-FSP1-CoQ10 axis for targeted human trials.
To investigate whether SIRT1 alleviates hypertensive cardiac remodeling by regulating the FSP1-CoQ10 axis to inhibit ferroptosis and mitochondrial dysfunction. In vivo, a hypertensive model was established in C57BL/6 J mice by chronic Angiotensin II (Ang II) infusion. In vitro, H9c2 and primary rat cardiomyocytes were treated with Ang II. siRNA-mediated SIRT1 knockdown was used to validate target specificity. SIRT1-FSP1 interaction was assessed via co-immunoprecipitation, acetylation, and ubiquitination assays. Cardiac structure and function were evaluated by echocardiography, histology, and transmission electron microscopy. Mitochondrial function was assessed by measuring oxygen consumption rate (OCR), mitochondrial membrane potential, and ATP content. SIRT1 expression was significantly downregulated in Ang II-treated cardiomyocytes and hypertensive mouse hearts. SIRT1 interacted with FSP1 and reduced its acetylation, thereby inhibiting ubiquitin-mediated degradation. Activation of SIRT1 or overexpression of FSP1 attenuated Ang II-induced ferroptosis, lipid peroxidation, and mitochondrial damage, whereas inhibition of SIRT1 or FSP1 exacerbated these effects. Consistently, SIRT1 knockdown further reduced FSP1 and exacerbated Ang II-induced ferroptosis, which was partially reversed by FSP1 overexpression. In vivo, SIRT1 activation or FSP1 overexpression ameliorated cardiac hypertrophy, fibrosis, and dysfunction induced by Ang II. CoQ10 supplementation rescued mitochondrial dysfunction and ferroptosis under FSP1 inhibition, indicating that CoQ10 acts downstream of FSP1. SIRT1 protects against hypertensive cardiac remodeling by deacetylating FSP1 and stabilizing the FSP1-CoQ10 axis, thereby suppressing ferroptosis and preserving mitochondrial function. The SIRT1-FSP1-CoQ10 axis may be a potential therapeutic target for hypertensive cardiac remodeling. A limitation is the lack of a genetic knockout model.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied Hypertensive cardiac remodeling. SIRT1 activation or FSP1 overexpression (and CoQ10 supplementation) vs. SIRT1 or FSP1 inhibition/knockdown or untreated Angiotensin II control was evaluated on Hypertensive cardiac remodeling (cardiac hypertrophy, fibrosis, and dysfunction), ferroptosis, and mitochondrial function. SIRT1 activation or FSP1 overexpression attenuated Ang II-induced ferroptosis, mitochondrial damage, and hypertensive cardiac hypertrophy, fibrosis, and dysfunction in mice and cardiomyocytes.
Synapse has enriched 10 related papers. Consider them for comparative context: